Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sinopharm Group Co ( (HK:1099) ) has provided an update.
Sinopharm Group Co. Ltd. announced the resignation of Mr. Chen Fangruo as an independent non-executive director due to the completion of his term. The company expressed gratitude for his contributions to its development and governance. Concurrently, the board proposed the appointment of Mr. Chen Weiru as a new independent non-executive director, pending shareholder approval. Mr. Chen Weiru brings extensive experience in strategy formulation and corporate management, which is expected to enhance the board’s diversity and strategic capabilities.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company is known for its focus on healthcare products and services, including the distribution of pharmaceuticals, medical devices, and other healthcare-related products.
YTD Price Performance: -14.18%
Average Trading Volume: 1,611
Technical Sentiment Signal: Buy
Current Market Cap: $7B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.